Why Amarin (AMRN) Stock Is Plummeting Today

NEW YORK (TheStreet) -- Shares of Amarin  (AMRN) plunged 23.76% to $1.38 Friday after the company announced that the FDA denied its appeal to reinstate Special Protocol Assessment status on a phase III study of the company's prescription fish-oil pill Vascepa.

John Jenkins, the head official in the FDA's Office of New Drugs, denied the appeal. This is the third time Amarin has been rejected when appealing for the SPA for Vascepa. Amarin said it is considering its next move.

More than 8.1 million shares had changed hands as of 11:34 a.m., compared to the average volume of 2,348,200.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AMRN Chart AMRN data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

If you liked this article you might like

Biotech Premarket Movers: Cempra, Novavax, Ionis

Biotech Premarket Movers: Cempra, Novavax, Ionis

Amarin (AMRN) Stock Drops After Pricing Public Offering

Amarin (AMRN) Stock Drops After Pricing Public Offering

Tetraphase Executive Profits Hours Before Stock Plummets

Tetraphase Executive Profits Hours Before Stock Plummets

5 Stocks Ready for Breakouts -- Must-See Charts

5 Stocks Ready for Breakouts -- Must-See Charts

3 Stocks Under $10 Making Big Moves

3 Stocks Under $10 Making Big Moves